학술논문

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
Document Type
article
Source
HemaSphere, Vol 7, p e10648ed (2023)
Subject
Diseases of the blood and blood-forming organs
RC633-647.5
Language
English
ISSN
2572-9241